[go: up one dir, main page]

MA29487B1 - Preparation de type emulsion stable - Google Patents

Preparation de type emulsion stable

Info

Publication number
MA29487B1
MA29487B1 MA30421A MA30421A MA29487B1 MA 29487 B1 MA29487 B1 MA 29487B1 MA 30421 A MA30421 A MA 30421A MA 30421 A MA30421 A MA 30421A MA 29487 B1 MA29487 B1 MA 29487B1
Authority
MA
Morocco
Prior art keywords
preparation
stable emulsion
emulsion type
emulsion
type
Prior art date
Application number
MA30421A
Other languages
English (en)
Inventor
Naoki Asakawa
Takayuki Doen
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37308111&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA29487(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of MA29487B1 publication Critical patent/MA29487B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Dispersion Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Detergent Compositions (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)

Abstract

LA PRÉSENTE INVENTION DÉCRIT UNE PRÉPARATION DE TYPE ÉMULSION QUI CONTIENT UN COMPOSÉ (A) STABLE EN MILIEU ACIDE ET UN AGENT TAMPON (B). LE PH DE CETTE PRÉPARATION DE TYPE ÉMULSION EST AJUSTÉ DE FAÇON À ÊTRE COMPRIS ENTRE ENVIRON 3,7 ET ENVIRON 5,5
MA30421A 2005-04-28 2007-11-26 Preparation de type emulsion stable MA29487B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2005131807 2005-04-28

Publications (1)

Publication Number Publication Date
MA29487B1 true MA29487B1 (fr) 2008-05-02

Family

ID=37308111

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30421A MA29487B1 (fr) 2005-04-28 2007-11-26 Preparation de type emulsion stable

Country Status (24)

Country Link
US (1) US20100016381A1 (fr)
EP (2) EP2255785A3 (fr)
JP (2) JP5236287B2 (fr)
KR (1) KR101321633B1 (fr)
CN (2) CN101212986B (fr)
AR (1) AR054264A1 (fr)
AU (1) AU2006241671B2 (fr)
BR (1) BRPI0610029A2 (fr)
CA (1) CA2605773C (fr)
CR (2) CR9495A (fr)
GE (1) GEP20105031B (fr)
IL (1) IL186673A (fr)
MA (1) MA29487B1 (fr)
ME (1) MEP10209A (fr)
MX (1) MX2007013407A (fr)
MY (1) MY147790A (fr)
NO (1) NO20075985L (fr)
NZ (1) NZ563225A (fr)
PE (1) PE20061437A1 (fr)
RU (1) RU2428204C2 (fr)
TW (1) TWI462745B (fr)
UA (1) UA97346C2 (fr)
WO (1) WO2006118329A1 (fr)
ZA (1) ZA200710193B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090105314A1 (en) * 2006-05-15 2009-04-23 Takeda Pharmaceutical Company Limited Pharmaceutical Agent
US20100062066A1 (en) * 2006-11-14 2010-03-11 Acusphere, Inc Formulations of Tetrahydropyridine Antiplatelet Agents for Parenteral or Oral Administration
US20080234376A1 (en) * 2007-03-21 2008-09-25 Taiwan Liposome Company (A Taiwan Corporation) Emulsion composition comprising prostaglandin e1
CN101229174B (zh) * 2008-01-25 2010-12-15 广东一品红药业有限公司 一种含有盐酸依匹斯汀的抗过敏组合物
US7829513B2 (en) * 2009-03-12 2010-11-09 Greenology Products, Inc. Organic cleaning composition
ES2560215T3 (es) 2010-01-27 2016-02-17 Takeda Pharmaceutical Company Limited Compuestos para la supresión de un trastorno de los nervios periféricos provocado por un agente anticanceroso
CN103458929A (zh) * 2011-03-31 2013-12-18 富士胶片株式会社 含有前列腺素的脂肪乳剂
JP2012214430A (ja) * 2011-03-31 2012-11-08 Fujifilm Corp プロスタグランジン含有脂肪乳剤
JP5894752B2 (ja) * 2011-03-31 2016-03-30 富士フイルム株式会社 プロスタグランジン含有脂肪乳剤
KR102200176B1 (ko) 2012-05-08 2021-01-11 에어로믹스, 인코포레이티드 신규 방법
MX386250B (es) 2013-11-06 2025-03-18 Aeromics Inc Formulaciones novedosas.
US20170246136A1 (en) * 2014-09-24 2017-08-31 OliVentures, Inc. Pharmaceutical product, medical food or dietary supplement for preventing cancer and inflammatory diseases
EP3454891A4 (fr) 2016-05-10 2019-12-25 The Regents of The University of Michigan Adjuvant en émulsion pour administration intramusculaire, intradermique et sous-cutanée
US20230248719A1 (en) * 2020-06-08 2023-08-10 Harm Reduction Therapeutics, Inc. Sterilized formulations

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5128339A (en) * 1990-11-01 1992-07-07 Sterling Winthrop Inc. Proteolytic enzyme inhibition method
US5380737A (en) * 1989-05-04 1995-01-10 Sterling Winthrop Inc. Saccharin derivative proteolytic enzyme inhibitors
US5236917A (en) * 1989-05-04 1993-08-17 Sterling Winthrop Inc. Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof
US5306818A (en) * 1990-11-01 1994-04-26 Sterling Winthrop Inc. Tetrahydro 2-saccharinylmerthyl aryl carboxylates
US5512589A (en) * 1990-11-01 1996-04-30 Sterling Winthrop Inc. 2-saccharinylmethyl aryl carboxylates useful as proteolytic enzyme inhibitors and compositions and method of use thereof
AU642537B2 (en) * 1990-11-01 1993-10-21 Sanofi 2-saccharinylmethyl aryl carboxylates useful as proteolytic enzyme inhibitors and compositions and method of use thereof
US5250696A (en) * 1990-11-01 1993-10-05 Sterling Winthrop Inc. 2-saccharinylmethyl aryl carboxylate
JP2836599B2 (ja) 1996-08-09 1998-12-14 日本電気株式会社 通信制御装置
HU230061B1 (hu) * 1998-03-09 2015-06-29 Takeda Pharmaceutical Company Limited Cikloalkénszármazékok, előállításuk és alkalmazásuk
CH693846A5 (de) 1998-03-11 2004-03-15 Mitsubishi Electric Corp Gronlingelektrode zur Oberflachenbehandlung durch Funkenerosion.
CA2380990A1 (fr) 1999-08-06 2001-02-15 Takeda Chemical Industries, Ltd. Composes a cycle aromatique substitues, procede de production, et utilisation
US6532316B1 (en) * 1999-11-10 2003-03-11 Avanex Corporation Bi-directional polarization-independent optical isolator
JP4863553B2 (ja) * 2000-02-04 2012-01-25 武田薬品工業株式会社 安定な乳化組成物
WO2001056562A1 (fr) * 2000-02-04 2001-08-09 Takeda Chemical Industries, Ltd. Compositions d'emulsions stables
JP2003033195A (ja) * 2001-07-24 2003-02-04 Kyowa Hakko Kogyo Co Ltd テトラヒドロクルクミン類の製造方法
US7960416B2 (en) * 2001-08-03 2011-06-14 Takeda Pharmaceutical Company Limited Stable emulsion composition
US20030220284A1 (en) * 2002-02-22 2003-11-27 Patricia Yotnda Delivery of adenoviral DNA in a liposomal formulation for treatment of disease
KR20050084178A (ko) * 2002-12-06 2005-08-26 가부시키가이샤 오츠까 세이야꾸 고죠 프로포폴 함유 지방 유제
NZ546231A (en) * 2003-10-03 2009-09-25 Ono Pharmaceutical Co Drug containing (2R)-2-propyloctanoic acid as the active ingredient
JPWO2007123186A1 (ja) * 2006-04-20 2009-09-03 武田薬品工業株式会社 医薬

Also Published As

Publication number Publication date
RU2007144071A (ru) 2009-06-10
JP2013040215A (ja) 2013-02-28
CN102670503A (zh) 2012-09-19
US20100016381A1 (en) 2010-01-21
MEP10209A (en) 2011-12-20
AU2006241671B2 (en) 2012-06-07
PE20061437A1 (es) 2007-01-25
AR054264A1 (es) 2007-06-13
UA97346C2 (ru) 2012-02-10
GEP20105031B (en) 2010-06-25
CN101212986A (zh) 2008-07-02
NZ563225A (en) 2011-01-28
EP1875926A1 (fr) 2008-01-09
TWI462745B (zh) 2014-12-01
NO20075985L (no) 2008-01-25
ZA200710193B (en) 2009-07-29
KR20080011413A (ko) 2008-02-04
IL186673A (en) 2013-08-29
EP2255785A2 (fr) 2010-12-01
CA2605773A1 (fr) 2006-11-09
MX2007013407A (es) 2008-01-15
CR20130666A (es) 2014-03-13
JPWO2006118329A1 (ja) 2008-12-18
WO2006118329A1 (fr) 2006-11-09
CA2605773C (fr) 2014-04-08
JP5236287B2 (ja) 2013-07-17
BRPI0610029A2 (pt) 2011-10-11
EP2255785A3 (fr) 2013-01-16
EP1875926A4 (fr) 2013-01-16
CR9495A (es) 2008-02-22
IL186673A0 (en) 2008-01-20
RU2428204C2 (ru) 2011-09-10
CN101212986B (zh) 2015-01-14
AU2006241671A1 (en) 2006-11-09
MY147790A (en) 2013-01-31
TW200724159A (en) 2007-07-01
KR101321633B1 (ko) 2013-10-22

Similar Documents

Publication Publication Date Title
MA29487B1 (fr) Preparation de type emulsion stable
TNSN05249A1 (fr) Benzopyrannes utiles pour le traitement d'etats inflammatoires
MA52486B1 (fr) Pyridazinones utilisés en tant qu'inhibiteurs de parp7
TNSN08196A1 (fr) Derives de pyrazine
MA45940B1 (fr) Composé hétérocyclique
TNSN01145A1 (fr) Derives d'imidazole a noyau aryle ou heteroaryle condense, et compositions les contenant.
WO2002086443A8 (fr) Procedes de diagnostic du cancer du poumon, compositions et procedes de criblage de modulateurs du cancer du poumon
TNSN02014A1 (fr) Composes nouveaux agonistes de ppar et compositions les contenant
MA63501B1 (fr) Dérivés d'urée pouvant être utilisés pour traiter le cancer
MA29160B1 (fr) Derives de triazole substitues, servant d'antagonistes d'ocytocine
EA200601002A1 (ru) 6-алкенил и 6-фенилалкил замещённые 2-хинолиноны и 2-хиноксалиноны в качестве ингибиторов поли(адф-рибоза) полимеразы
TNSN07305A1 (fr) Agonistes de pyy et leurs utilisations
TNSN02032A1 (fr) Derives de glutaramide a substituant n-phenpropylcyclopentyle nouveaux, et compositions les contenant.
EA200601007A1 (ru) 7-фенилалкилзамещённые 2-хинолиноны и 2-хиноксалиноны в качестве ингибиторов поли(адф-рибоза)полимеразы
TNSN99001A1 (fr) Indoles 2,3-substitues servant d'agents anti-inflammatoires et analgesiques
MA29723B1 (fr) Composes
MA63885A1 (fr) Composés inhibant l'isoforme alpha de pi3k et méthodes de traitement du cancer
ATE363474T1 (de) Benzimidazole zur behandlung sexueller fehlfunktionen
DE60217335D1 (de) Biozid wirkendes reinigungsmittel
FR3092115B1 (fr) analogues de GTP fluorescents et utilisation
PT1105114E (pt) Composicoes farmaceuticas topicas contendo nimesulide
MA30523B1 (fr) Compose tricylique et utilisation pharmaceutique de celui-ci
MA27661A1 (fr) Indolone-oxazolidinones antibacteriennes, intermediaires pour leur preparation et compositions pharmaceutiques les contenant
TNSN06370A1 (fr) Derives de pyrimidine pour le traitement d'une croissance cellulaire anormale
BRPI0416678A (pt) pirazolpirimidinas